AXL targeting induces NK-kB activation, resulting in enhanced expression of intercellular adhesion molecule 1 (ICAM1) and UL16 binding protein 1 (ULBP1) along with MAPK inhibition, finally improving the survival of patients with NSCLC. Here, ICAM1 is linked to non-small cell lung carcinoma.